Targeted NDA/ANDA Novelstar focuses on developing NDA and ANDA with advanced drug delivery systems, suggesting sales opportunities in regulatory affairs support, formulation services, and specialized packaging or delivery technologies that align with government NDA/ANDA submission needs.

Parent-backed Scale As a Fosun Pharma subsidiary, Novelstar may benefit from distribution channels, manufacturing partnerships, and co-development opportunities within a large, established global health ecosystem, enabling faster market access and bulk purchasing advantages.

Small but nimble With a lean team size (2-10 employees), there is potential for continuous outsourcing of R&D, regulatory consulting, and contract manufacturing services, offering scalable collaboration models for incremental project wins.

Technology stack fit Their use of modern web and compliance tools indicates readiness for digital collaboration, secure documentation, and e-submission workflows, suggesting opportunities for CDMO partnerships that emphasize quality systems and regulatory readiness.

Growth potential Revenue in the low to mid millions places Novelstar in a growth segment with room for expanded product lines, clinical-to-commercial transitions, and strategic alliances around specialized drug delivery platforms and lifecycle management.